RxDoctor Payments DataLook up a doctor →

Ricardo Gonzalez, MD

Family Medicine · Reno, NVNPI 1326011297

Payments from drug & device makers

$11,249in general payments, 2019–2025

Across 609 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • GSK$1K
  • Pfizer$652
  • Boehringer Ingelheim$619
  • Amgen$570
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$11,13099%
  • Education$1191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,249 in reported general payments places this provider in the 95th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$60,435
Medicare patients
299
Services billed
652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin61$83,894
OzempicSemaglutide64$83,769
MounjaroTirzepatide43$46,659
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$44,113
EliquisApixaban37$36,059
FarxigaDapagliflozin Propanediol25$27,750
RybelsusSemaglutide12$23,921
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$14,545
MyrbetriqMirabegron20$13,424
Breo ElliptaFluticasone/Vilanterol17$9,455
LinzessLinaclotide14$8,417
Nebivolol Hcl23$4,614
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen217$4,323
Atorvastatin Calcium278$4,317
SynthroidLevothyroxine Sodium45$4,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$444$107,69076 claims
Boehringer IngelheimJardiance$619$83,89461 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$1,118$55,83278 claims
Lilly USA, LLCMounjaro$349$46,65943 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,525$42,29548 claims
PfizerEliquis$652$36,05937 claims
Astellas Pharma US IncMyrbetriq$334$13,42420 claims
AbbVieLinzess, Synthroid$2,276$12,66759 claims
BayerClimara Pro$164$2,72611 claims
Scilex Pharmaceuticals Inc.Colchicine$71$1,59423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 902 family medicine providers in Nevada.

Other family medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →